Zhitong Finance App News, Sinqi Pharmaceutical (300573.SZ) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” for SQ-23082 eye drops issued by the State Drug Administration. SQ-23082 eye drops are a Class 2.1 improved new chemical developed by the company. Clinically intended for the treatment of itchy eyes associated with allergic conjunctivitis. According to the requirements of the improved new drug, the company has completed research on various aspects such as pharmacology and non-clinical pharmacology and toxicology of the SQ-23082 eye drops. The research results show that the SQ-23082 eye drops have good safety and clinical development value. Currently, there are no such ophthalmic products on the market at home or abroad.

Zhitong Finance App News, Sinqi Pharmaceutical (300573.SZ) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” for SQ-23082 eye drops issued by the State Drug Administration. SQ-23082 eye drops are a Class 2.1 improved new chemical developed by the company. Clinically intended for the treatment of itchy eyes associated with allergic conjunctivitis. According to the requirements of the improved new drug, the company has completed research on various aspects such as pharmacology and non-clinical pharmacology and toxicology of the SQ-23082 eye drops. The research results show that the SQ-23082 eye drops have good safety and clinical development value. Currently, there are no such ophthalmic products on the market at home or abroad.